Alpha 2.0
Login Register
» Articles » PMID: 39463880

Predictors of Drug Retention and Survival Rate of BDMARDs in Rheumatoid Arthritis: A Four-Year Real-Life Tunisian Experience

Overview
Journal Mediterr J Rheumatol
Specialty Rheumatology
Date 2024 Oct 28
PMID 39463880
Authors
Soumaya Boussaid
Houssem Tbini
Sonia Rekik
Saadaoui Khaled
Safa Rahmouni
Khaoula Zouaoui
Salem Riahi
Hela Sahli
Mohamed Elleuch
Affiliations
Soon will be listed here.
Abstract

Introduction: This study aims to investigate the efficacy and tolerance of biologic disease-modifying anti-rheumatic drug (bDMARDs) in the current management of rheumatoid arthritis (RA) by identifying the retention time and survival rate of bDMARDs.

Materials And Methods: We conducted a retrospective cohort study including Tunisian patients initiating bDMARD treatment between 2016 and 2018 whose data were collected from the National Health Insurance Fund (NHIF). The NHIF is the national office which organises and centralises patients under bDMARDs from all over the country. Retention and survival rate of bDMARDs at 48 months were analysed using Kaplan-Meier survival curves and compared using the log-rank test. Survival factor analysis was performed using Cox regression.

Results: Three hundred seventy-four patients, aged 55.5±12.5years [20-90], (87.2%women), were included. The mean duration of RA was 11.7±6.7 years [2-41]. The mean disease activity score (DAS)28 at initiation of the first bDMARD was 6.01±0.89 [5.37-6.5]. This first bDMARD induced low disease activity (LDA) in 55% of cases. Remission was observed in 28% of patients. The highest LDA and remission rates were observed with Tocilizumab (70.8% and 33.3% of cases, respectively). LDA and remission were achieved within a mean of 45 weeks [26-88] and 72 weeks [31-117] respectively. The 48-month first-line survival rate was 55.9%. Retention time was 41.7 months, 95%CI [39.47-43.91]. Presence of rheumatoid factors, co-prescription of methotrexate, and good initial therapeutic response were factors influencing better survival of bDMARDs (p<0.01). Glucocorticoid use predicted poorer survival (p<10-3). The first bDMARD was interrupted in 39% of cases. Ineffectiveness was the most common cause of treatment cessation (52.7%).

Conclusion: This real-life study of the Tunisian population allowed us to establish the factors that can influence the survival and retention rates of bDMARDs.

References
1.
Nakayama Y, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H . Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study. Rheumatol Int. 2022; 42(7):1227-1234. DOI: 10.1007/s00296-021-05086-w. View
2.
Svensson B, Andersson M, Bala S, Forslind K, Hafstrom I . Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open. 2013; 3(9):e003554. PMC: 3773654. DOI: 10.1136/bmjopen-2013-003554. View
3.
Keystone E, Landewe R, van Vollenhoven R, Combe B, Strand V, Mease P . Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis. 2013; 73(12):2094-100. PMC: 4251202. DOI: 10.1136/annrheumdis-2013-203695. View
4.
Jung S, Lee S, Song J, Park S, Park Y . Drug Survival of Biologic Therapy in Elderly Patients With Rheumatoid Arthritis Compared With Nonelderly Patients: Results From the Korean College of Rheumatology Biologics Registry. J Clin Rheumatol. 2020; 28(1):e81-e88. DOI: 10.1097/RHU.0000000000001644. View
5.
Gabay C, Riek M, Scherer A, Finckh A . Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford). 2015; 54(9):1664-72. DOI: 10.1093/rheumatology/kev019. View